The estimated Net Worth of Venture Fund Vii, L.P.Arch ... is at least $9.75 millió dollars as of 15 July 2019. Venture Arch owns over 63,000 units of Syros Pharmaceuticals stock worth over $6,829,702 and over the last 7 years Venture sold SYRS stock worth over $2,920,223.
Venture has made over 3 trades of the Syros Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently Venture sold 63,000 units of SYRS stock worth $489,510 on 15 July 2019.
The largest trade Venture's ever made was selling 167,503 units of Syros Pharmaceuticals stock on 12 March 2019 worth over $1,311,548. On average, Venture trades about 98,772 units every 32 days since 2018. As of 15 July 2019 Venture still owns at least 4,242,051 units of Syros Pharmaceuticals stock.
You can see the complete history of Venture Arch stock trades at the bottom of the page.
Over the last 8 years, insiders at Syros Pharmaceuticals have traded over $8,259,551 worth of Syros Pharmaceuticals stock and bought 5,052,185 units worth $51,830,966 . The most active insiders traders include Group, Llc Green Jeremy Red..., Srinivas Akkaraju és Stephane Bancel. On average, Syros Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $135,148. The most recent stock trade was executed by Richard A Young on 28 June 2024, trading 34,837 units of SYRS stock currently worth $178,365.
syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
Syros Pharmaceuticals executives and other stock owners filed with the SEC include: